The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (47.63) USD. With the latest stock price at 2.41 USD, the upside of Immunitybio Inc based on DCF is -2076.4%.
Based on the latest price of 2.41 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 2076.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.9% - 9.4% | 8.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (99.88) - (32.20) | (47.63) |
| Upside | -4244.3% - -1436.2% | -2076.4% |